Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...
Hosted on MSN7d
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...
Today's Research Daily features a real-time update on the Q4 earnings season and fresh Chevron (CVX), Merck (MRK), QUALCOMM ...
Hosted on MSN15d
Merck Just Paid Investors: How Much Did They Receive?and monitoring products. Merck has development and commercialization agreements with AstraZeneca, Daiichi Sankyo, and LaNova. It also has collaboration agreements with Bayer, Eisai, Moderna ...
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
Merck, a leading science and technology company, today launched a beta version of M-Trust, a secure cyber-physical trust ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback